VAQTA Injection
Hepatitis A Vaccine (HAV Antigen)
25 U/Dose
Merck Sharp & Dohme B.V.
| Pack size | 1 Dose (0.5ml) Vial |
|---|---|
| Dispensing mode | POM |
| Source | NETHERLANDS |
| Agent | CITY MEDICAL STORE |
| Retail Price | 103.00 AED |
Available as:
Indications
VAQTA Injection is used for:
Active immunisation against Hepatitis A virus
Adult Dose
Intramuscular
Active immunisation against hepatitis A
Adult: 2-dose vaccination series: 1 mL IM; separate the 2 doses by 6-12 months
Child Dose
Intramuscular
Active immunisation against hepatitis A
Child: Indicated as routine vaccination for children at least 12 months of age (ACIP guidelines)
<12 months: Not indicated
Routine vaccination (2-dose series): 0.5 mL IM initiated at aged 12 through 23 months; separate the 2 doses by 6-12 months
Children who have received 1 dose before age 24 months, should receive a second dose 6-12 months after the first dose
Catch up schedule
For any person >2 yr who has not already received hepatitis A vaccine series, give 2 doses separated by 6-18 months if immunity against hepatitis A virus infection is desired
Minimum interval between the 2-dose series is 6 months
Renal Dose
Administration
Contra Indications
Hypersensitivity. Vaccines prepared in egg cultures are contraindicated in patients with hypersensitivity reactions to egg. Severe immunodeficiency. Malignant disease being treated with chemotherapy or radiotherapy and for at least 6 mth after stopping treatment. Patients with compromised immune system such as those on high-dose systemic corticosteroids, immunosuppressants or HIV positive.
Precautions
Alcohol or disinfectant used for cleaning the skin prior to inj should be allowed to evaporate completely before vaccination to prevent vaccine inactivation.
Lactation: not established
Pregnancy-Lactation
Interactions
Reduced response to vaccination when used concurrently with immunosuppressants such as corticosteroids or antineoplastics.
Adverse Effects
Side effects of Hepatitis A Vaccine (HAV Antigen) :
>10%
Injection site tenderness (3-56%), erythema (1-22%), warmth (1-17%), swelling (9-11%), Irritability (11-36%), Anorexia (1-19%), Drowsiness (15-17%), Headache (1-16%), Fever > 100.4 F (9-11%)
1-10%
URI (1-10%), Otitis media (8%), Rhinorrhea (6%), Diarrhea (1-6%), Cough (1-5%), Rash (1-5%), Weakness/fatigue (4%), Vomiting (1-4%), Fever > 102 F (3%), Crying (2%)
<1%
Hematoma, Incr. CPK, Photophobia, Vertigo
Potentially Fatal: Anaphylaxis.
Mechanism of Action
Hepatitis A antigen is prepared from formaldehyde-inactivated hepatitis A virus grown in human diploid cells. It is used for active immunisation against hepatitis A infection.
Note
VAQTA 25 U/Dose Injection manufactured by Merck Sharp & Dohme B.V.. Its generic name is Hepatitis A Vaccine (HAV Antigen). VAQTA is availble in United Arab Emirates.
Farmaco UAE drug index information on VAQTA Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.